The oral solid dosage excipients market is poised for remarkable expansion, exhibiting a robust CAGR of 7.9%. With an estimated value of US$ 5.9 billion, this surge underscores the escalating demand for these essential pharmaceutical components.
The report "Oral Solid Dosage Excipients Market, By Product Type (Glycerin, Propylene Glycol, Sorbitol, Mannitol and Others), By Form (Crystal, Powder and Others), By Application (Industrial and Non-Industrial) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”
Sample link:
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4638
Key Highlights:
• Demand for custom drug delivery solutions is increasing and bringing forth an exciting period of valuable, innovative development opportunities.
• On 7th Dec, 2020, Evonik acquired Birmingham-Based LACTEL Absorbable Polymers from DURECT Corporation.
Analyst view:
Industry Analysts Optimistic: Market observers express a positive outlook on the oral solid dosage excipients sector, citing a projected CAGR of 7.9% and a value of US$ 5.9 billion. This growth is attributed to increasing pharmaceutical demand, indicating a promising future for these critical components.
Competitive Landscape:
The key players operating in the Global Oral Solid Dosage Excipients Market include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson and Johnson, Biogen Inc., Bayer AG, Teva Pharmaceuticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co. Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc.
To know more
Contact Us:
Sales
Prophecy Market Insights
U.S. 1 860 531 2574
RoW: 917775049802
Email- [email protected]
Website- www.prophecymarketinsights.com
Blog- www.prophecyjournals.com